摘要
目的研究厄贝沙坦联合辛伐他汀对早期糖尿病肾病(Diabetic nephropathy,DN)患者的治疗效果。方法将152例DN患者随机分为两组,对照组76例采用厄贝沙坦治疗,治疗组76例在厄贝沙坦治疗的基础上加用辛伐他汀。两组分别于治疗前和治疗后12周检测血压(SBP和DBP)、空腹血糖水平(FBG)、尿微量白蛋白排泄率(UAER)、尿β2微球蛋白(β2-MG)、血尿素氮(BUN)、血肌酐(SCr)、总胆固醇(TG)、甘油三酯(TC)。结果治疗后,对照组中除BUN、SCr、TG和TC外,SBP、DBP、FBG、UAER和β2-MG均较治疗前显著降低,差异有统计学意义(P<0.05)。治疗组中除BUN和SCr外,SBP、DBP、FBG、UAER、β2-MG、TG和TC均较治疗前明显降低,差异有统计学意义(P<0.05);且治疗组降低UAER、β2-MG、TG和TC的效果均明显优于对照组,差异有统计学意义(P<0.05)。结论厄贝沙坦联合辛伐他汀治疗早期糖尿病肾病,可以更好地降低患者的血脂、UAER和β2-MG,显著提高了临床治疗效果。
Objective To study the therapeutic effect of irbesartan and simvastatin on early diabetic nephropathy （DN）. Methods 152 patients with DN were randomly divided into two groups. Patients in control group （n=76） were given therapy with irbesartan （150mg/d）. On the basis of therapeutic scheme, the patients in treatment group （n= 76） were treated with simvastatin （20mg/d）. Systolic blood pressure （SBP）, diastolic blood pressure （DBP）, fasting blood sugar （FBG）, urine albumin excretion rate （UAER）, urine β2-microglobulin （β2-MG）, blood urea nitrogen（BUN） and serum creatinine （SCr）, total cholesterol （TG） and triglyceride （TC） were tested before and twelve weeks after treat- ment. Results After treatment, there were significant differences in SBP, DBP, FBG, UAER and β2-MG before and af- ter treatment in control group （P〈0.05）. There were significant differences in SBP, DBP, FBG, UAER, β2-MG, TG and TC all before and after treatment in treatment group（P〈0. 05）. The effect of controlling UAER, β2-MG, TG and TC were better than that of the control group （P〈0.05）. Conclusions Treating DN with irbesartan and simvastatin can significantly decrease blood-fat, UAER and β2-MG.
出处
《西部医学》
2012年第11期2086-2088,共3页
Medical Journal of West China
关键词
厄贝沙坦
辛伐他汀
糖尿病肾病
疗效
Irbesartan
Simvastatim Diabetic nephropathy
Therapeutic effect
